GUARDSQUARE
5.3.2019 16:02:12 CET | Business Wire | Press release
Guardsquare, a market-leading security company specializing in protecting the next generation of complex mobile applications, has appointed René Bonvanie, the CMO of Palo Alto Networks, to its board of directors. Felix Van de Maele, the CEO and co-founder of Belgian data company Collibra—a “unicorn” valued at US$1 billion—is joining as a board advisor.
Guardsquare—a company at the forefront of helping enterprises manage the digital transformation of their businesses—makes a widely used open-source security platform already in use with over a million apps to enable agile software innovation. Specifically, the company’s technology protects increasingly critical mobile apps, usually being deployed outside corporate firewalls, from dangerous security threats. Guardsquare is pioneering mobile and IoT application security in a world where over 20 billion connected devices are expected to be running applications at the edge by 2020. Earlier this year, Guardsquare announced a $29 million investment from Battery Ventures. As part of the transaction, Battery General Partner Dharmesh Thakker and Battery Principal Paul Morrissey joined Guardsquare’s board of directors.
The board now welcomes René Bonvanie as a new member. Bonvanie has more than thirty years of executive management and marketing experience in enterprise technology and has led marketing at Palo Alto Networks since 2009. Bonvanie also serves on the board of IoT security company Armis and, prior to his current role at Palo Alto Networks, had executive marketing roles at Business Objects, VERITAS, and Oracle.
Bonvanie stated: “The cybersecurity landscape is evolving rapidly because of the increasing adoption of connected devices and the advent of new technologies such as 5G. Guardsquare provides security capabilities that are increasingly critical in this changing landscape. I look forward to using my European background and security expertise to drive the adoption of Guardsquare’s products on both sides of the Atlantic.”
Felix Van de Maele will join as a board advisor. Van de Maele is the CEO and co-founder of Belgian unicorn Collibra, a leader in enterprise data governance and catalog software. He brings to the table an impressive track-record in scaling a high-tech European enterprise and gaining a strong foothold in the US market.
“Using the experience I gained with Collibra, I am looking forward to providing strategic advice to Guardsquare’s board—and am excited to help another Belgian tech company to expand in the US,” Van de Maele said.
“Bonvanie and Van de Maele both have in-depth knowledge of the software industry and its needs,” said Roel Caers, CEO of Guardsquare. “They believe that our company’s mobile security solutions are important for any organization operating in this mobile-first world. Both men will join forces with Belgian fintech pioneer and Guardsquare board member Jurgen Ingels to accelerate Guardsquare’s growth.”
About Guardsquare
Guardsquare is the global reference in mobile application protection. It was founded in 2014 by Heidi Rakels, Guardsquare’s current president, and Eric Lafortune, now CTO of the company. Guardsquare develops premium software for the protection of mobile applications against reverse engineering and hacking. Their products are used across the world in a broad range of industries, from financial services, e-commerce and the public sector to telecommunication, gaming and media. Guardsquare is based in Leuven (Belgium) and San Francisco. Read more on www.guardsquare.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005055/en/
Contact:
Steven Surdiacourt steven.surdiacourt@guardsquare.com +32 (0)16 920 646
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom